Postby NHMike » Sat May 19, 2018 11:59 am
dauofcamom wrote:My mom is having genetic testing on her tumor. She is MSI. I’m confused by some things I’ve read. Would/should her treatment change from Xelox regime to something different?
Forgive me for not remembering but there were 4 things that are indicators (not sure if that’s the right terminology). She has defective MLH1 and PMS2 but her MSH2 and MSH6 were normal.
What should I know?
Cecum tumor
G3
T4bN1aM0
Margins clear.
They want to know the Gene Mutations of the tumor. It can be useful in some cases to determine that she has an aggressive mutation. In some cases, it may be useful for treatment. There aren't a lot of options for CRC at this point, besides the usual treatments, but I expect that to change a lot in the next year or two.
6/17: ER rectal bleeding; Colonoscopy
7/17: 3B rectal. T3N1bM0. 5.2 4.5 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6, 5 x 5
7/17-9/17: Xeloda radiation
7/5: CEA 2.7; 8/16: 1.9; 11/30: 0.6; 12/20 1.4; 1/10 1.8; 1/31 2.2; 2/28 2.6; 4/10 2.8; 5/1 2.8; 5/29 3.2; 7/13 4.5; 8/9 2.8, 2/12 1.2
MSS, KRAS G12D
10/17: 2.7 2.2 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 (-75%), 5 x 3 (-40%). 5.1 CM from AV
10/17: LAR, Temp Ileostomy, Path Complete Response
CapeOx (8) 12/17-6/18
7/18: Reversal, Port Removal
2/19: Clean CT